EcoR1 Capital — Full Portfolio

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.

BiotechHealthtechMedical DevicesThousand Oaks, US

AnhCo Nguyen(President and Chief Executive Officer)Isaac Ciechanover(Founder)

Co-investorsDADag VenturesHEHEALTHCARE ROYALTY PARTNERSKLKleiner PerkinsDODomain AssociatesFIFidelity Investments

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

PSPaul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

BoardANAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCACardinal PartnersSOSofinnova VenturesVIViking GlobalDODomain AssociatesDODomain PartnersPOPolaris Partners+2 more

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

MHMichael Heffernan(Executive Officer, Director)inPBPaul Brannelly(Executive Officer)inVKVikram Karnani(President and Chief Executive Officer, and Director)in

BoardEran Nadav(Director)John Freund(Director)PHPatrick Heron(Director)in

Co-investorsAPAPERTURE Venture PartnersFRFrazier Life SciencesLOLongitude CapitalBOBoston Millennia PartnersRARA Capital

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)MGMark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)

Co-investorsPAPappas CapitalABAberdare VenturesINInvusPOPolaris Partners

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

MTMarc Tessier-Lavigne(Founder)inAOAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSESteve E. Krognes(Director)inAlexander Schuth(Founder)

Co-investorsARARCH Venture PartnersF-F-Prime CapitalFOForesite CapitalGVGV (Google Ventures)FLFlagship PioneeringFLFlagship Ventures

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang(Founder)inGCGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDLDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKBKatrine Bosley(Executive Officer, Director)inVMVic Myer(Executive Officer)in

Co-investorsGVGV (Google Ventures)SOSofinnova VenturesVIViking GlobalATAtlas VentureDEDeerfield Management CompanyFLFlagship Ventures+2 more

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

RERiley Ennis(Founder)inCharles Roberts(Founder)inGOGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRARA CapitalAGAgent CapitalAMAME Cloud VenturesANAndreessen HorowitzARArtis VenturesASAsset Management Company+14 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARARCH Venture PartnersBABay City CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)PIPivotal Life SciencesSASamsara BioCapital+3 more

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Founder)inJennifer Doudna(Founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsAGage1ATAtlas VentureAVAvoro Capital AdvisorsFOForesite CapitalOROrbiMedRIRidgeback Capital+2 more

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

PINGDA REN(Executive Officer)inYLYI LIU(Executive Officer)inTWTroy Wilson(Founder)inTWTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsFOForesite CapitalNENextech InvestOUOUP (Osage University Partners)AVAvoro Ventures

Neurogene develops gene therapy treatments for rare neurological diseases.

BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US

RMRachel McMinn(Founder and Chief Executive Officer)inRMRachel McMinn, Ph.D.(Founder and Chief Executive Officer)

BoardCory Freedland(Director)inStephen Biggar(Director)

Co-investorsSASamsara BioCapitalCACasdin CapitalREREDMILERTRTW Investments L.P.WIWilliam Blair

Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.

BiotechHealthtechNew York, US

DHDavid Hung(Founder)inDavid Hanley(Chief Technical Operations Officer)inGHGary Hattersley(Chief Scientific Officer)inSMStacy Markel(Chief People Officer)inPSPhilippe Sauvage(Chief Financial Officer)inCSColleen Sjogren(Chief Commercial Officer)in

Co-investorsAIAisling CapitalDEDecheng CapitalVEVertex Ventures ChinaOMOmega Funds

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

RHRichard Heyman(Chairman, Founder, Scientific Advisory Board)inCSCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)DPDominic Piscitelli(Chief Financial Officer)inPMPratik Multani(Chief Medical Officer)inJCJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsNENew Enterprise Associates (NEA)NENextech InvestTATaiho Ventures, LLCTHThe Column GroupVIViking GlobalOROrbiMed

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)inSKSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCOCommonweal VenturesFOForesite CapitalNANat TurnerNENextech InvestSOSoftBank Vision FundCUCurie.Bio+2 more

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

NMNagesh Mahanthappa(Executive Officer, Director)inTSTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAVAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVSVikas Sinha(Chief Financial Officer)in

Co-investorsAIAisling CapitalARARCH Venture PartnersPOPolaris PartnersTHThe Kraft Group

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in

Co-investorsSASamsara BioCapitalARARCH Venture PartnersPOPolaris Partners

Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.

BiotechHealthtechAustin, US

JHJosiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)

BoardWalter Loewenbaum(Director)

Co-investorsHAHatteras Venture PartnersOROrbiMedRORocky Point VenturesREREDMILET.T. Rowe Price

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inAMArlene Morris(Executive Officer, Director)inMAMichael A. Metzger(Chief Executive Officer)inKAKeith A. Goldan(Chief Financial Officer)in

BoardDPDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsAIAisling CapitalATATEM Capital FundAVAvoro Capital AdvisorsBIBioBritDEDelos CapitalFOForesite Capital+6 more

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

RYRichard Young, Ph.D.(Director)inAHAnthony Hyman, Ph.D.(Director)THTony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Co-investorsARARCH Venture PartnersGEGeneral CatalystSASamsara BioCapital6 6 Dimensions CapitalINInnovation EndeavorsLELeaps by Bayer+6 more

Epikast provides AI-powered tools for medical science liaisons and field teams to analyze clinical interactions with physicians and patients, and to access synthesized scientific information in their disease areas.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBrooklyn, US

Evangelos Vergetis(Executive Officer, Director)

BoardBrad Prosek(Director)Stelios Papadopoulos(Director)Daphne Karydas(Director)Alexandros Tzoukas(Director)

Board seatONOleg Nodelman· per SEC Form D

Co-investorsVEVedanta Capital

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Board seatONOleg Nodelman· per SEC Form D

Co-investorsAJAju IB InvestmentEVEvolution VC PartnersMPMPM BioImpactOROrbiMedOUOUP (Osage University Partners)PFPfizer Venture Investments+6 more

BiotechBoston, US

AFAdam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Board seatONOleg Nodelman· per SEC Form D

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsFRFrazier Life SciencesNENextech InvestVIVida VenturesABAbingworth+4 more

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsATAtlas VentureDRDroia VenturesGVGV (Google Ventures)THThe Column GroupABAbbVieJJJJDC+3 more

Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions.

BiotechDeep Tech

DBDavid Breckenridge(Founder)inDavid B. Goldstein(Founder)

Co-investorsCACanaan PartnersDRDroia Ventures

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)ATAaron Tward, M.D., Ph.D.(Scientific Co-Founder)BRBotond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)RDRami Daoud(Executive Officer)inRMRick Modi(Chief Executive Officer, Board Member)

Co-investorsATAtlas VentureEIEight Roads VenturesF-F-Prime CapitalGVGV (Google Ventures)NENew Enterprise Associates (NEA)TCTCG Crossover+1 more

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)SBSteven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBABain Capital Life SciencesFOForesite CapitalBABain CapitalRORock Springs CapitalT.T. Rowe Price

Ajax Systems produces wired and wireless intrusion protection devices for professional security installations, offered through two product lines: Baseline for general projects and Ajax Superior for advanced, high-security applications that require partner accreditation and training.

AI & Machine LearningCybersecurityEnterprise SoftwareHardwareIoT

Aleksandr Konotopskyi(Founder)inOleksandr Konotopskyi(Founder)

Co-investorsENEndeavor CatalystHOHorizon CapitalRERevelation Partners

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsINInning One VenturesRARA CapitalRERevelation PartnersVIVivo Capital

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

ESEmmanuel Simons(Executive Officer, Director)WSwilliam sewell(Founder)in

BoardEMEd Mathers(Director)inKPKush Parmar(Director)in

Co-investors5A5AM VenturesNENew Enterprise Associates (NEA)PIPivotal Life SciencesRARA CapitalSOSofinnova VenturesCOCowen Healthcare Investments+2 more

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing retinal disease treatments, specifically engineered biologics for wet AMD, diabetic eye disease, and retinal vein occlusion.

BiotechDigital HealthMedical DevicesBerkeley Heights, US

NFNapoleone Ferrara(Director & Co-Founder)SASrinivas Akkaraju(Director & Co-founder)MDMike Dybbs(Director & Co-founder)

A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.

BiotechDigital HealthHealthtechMedical DevicesMental HealthIndianapolis, US

JGJaswant Gidda(Executive Officer, Director)inJames Schulz(Executive Officer)Yvonne Lai(Executive Officer)

BoardNora Doherty(Director)Derek Small(Director)Anantha Shekhar(Director)

Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.

BiotechHealthtech

Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRMRichard Markus(Chief Medical Officer)inCTCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)

Co-investorsAIAisling CapitalDEDecheng CapitalDRDroia VenturesFOForesite CapitalGVGV (Google Ventures)SLSLVC+4 more

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.

BiotechHealthtechMedical DevicesSan Diego, US

Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)FAFred Aslan(Executive Officer, Director)inJLJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)PFPeter Flynn(Executive Officer)in

Co-investors5A5AM VenturesRARA CapitalVEvenBio PartnersWEWellington ManagementVEvenBio Global Strategic

BiotechRedwood City, US

William Robinson(Director)LSLawrence Steinman(Director)TSTito Serafini(Executive Officer, Director)

BoardBrian Atwood(Director)Franklin Berger(Director)

Co-investorsAIAisling CapitalEVEvolution VC PartnersMIMission Bay CapitalMIMission Biocapital

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTFTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)ZOZaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsFRFrazier Life SciencesILIllumina VenturesNENextech InvestSASanofi VenturesVIVida VenturesGOGoldman Sachs+1 more

AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases.

BiotechDigital HealthHealthtechMedical Devices

GMGeorge Montgomery(Executive Chairman)

Co-investorsEVEvolution VC PartnersHEHelios CapitalPLPlum Alley InvestmentsSASand Hill AngelsTRTransform InvestmentsSOSocii Capital+1 more

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.

BiotechHealthtech

Neil Kumar(Founder)

Co-investorsAIAisling CapitalAMAmzak HealthFRFrazier Life SciencesHEHEALTHCARE ROYALTY PARTNERSLOLongwood FundSESequoia Capital+2 more

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.

Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US

FGFabian Gerlinghaus(Founder)inOKOmar Kurdi(Founder)inAlex Pesch(Founder)Fabian Gerlinghaus Omar Kurdi(Founder)

BoardJBJustin Butler(Director)inVTVictor Tong(Director)in

Co-investorsDEDecheng Capital8V8VCINIntuitive VenturesKOKoch Disruptive TechnologiesBABaillie GiffordBLBlackRock+4 more

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsADAdvent Life SciencesFOForesite CapitalLILifeSci Venture PartnersMEMedicxiOBOberland CapitalSCScion Life Sciences+4 more

Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.

BiotechSeattle, US

DWDoug Williams(Executive Officer, Director)in

BoardNANoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)

Co-investorsARARCH Venture PartnersALAlexandriaFIFidelity InvestmentsFLFlagship PioneeringQAQatar Investment Authority

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

CNChiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsIMImpact Ventures Management Pty LtdPAPacific Channel3E3E Bioventures CapitalARARCH Venture PartnersGEGeneral CatalystLELeaps by Bayer+3 more

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Alex Lugovskoy(Founder)Michael Gladstone(Founder)

Co-investorsATAtlas VentureFRFrazier Life SciencesRARA CapitalRVRV Invest GmbHSASanofi VenturesVIViking Global

Pioneering a drug discovery method based on tracking the movement of individual proteins in living cells.

Eric Betzig(Founder)Luke Lavis(Founder)Robert Tjian(Founder)Xavier Darzacq(Founder)

Co-investorsHOHorizons VenturesLULux CapitalTCTCG CrossoverTHThe Column GroupGEGeneral CatalystINInnovation Endeavors

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.

BiotechDeep TechHealthtechWaltham, US

DHDavid Hallal(CEO)inMPMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in

Co-investorsMPMPM BioImpactSASamsara BioCapitalSOSoftBank Vision Fund

Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.

BiotechDigital HealthHealthtechMedical Devices

Dr. Rod MacKinnon(Founder)

Co-investorsBEBessemer Venture PartnersLILightstone VenturesLOLongwood Fund

Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.

BiotechSouth San Francisco, US

JFJohn F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)

BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)

Co-investorsBABay City CapitalCHChiesi VenturesPAPappas CapitalQIQiming Venture Partners USASOSolasta VenturesCOCowen Healthcare Investments+1 more

Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)DMDavid M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsGVGV (Google Ventures)NENextech InvestVIVida VenturesBLBlackRockCOCommodore CapitalINInvus+2 more

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)inYLYi Liu, Ph.D.(CEO)Lynn Yang(Director)

BoardCGCarl Gordon(Director)in

Co-investorsOROrbiMedRORoche Venture Fund

A Korean-language service that brokers in-game currency ("money") and poker chips for the Pmang and Hangame poker platforms, letting players buy game money or cash out their holdings.

GamingMarketplaces

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Co-investorsAGage1LALAVLILifeSci Venture PartnersLILilly Asia VenturesNENew Enterprise Associates (NEA)VIVivo Capital+8 more

HealthtechWest Lafayette, US

Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)RMRonald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)

Co-investorsARArsenal Bridge VentureJAJanus Henderson InvestorsREREDMILE

BiotechDublin 1

Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)

Co-investorsAIAisling CapitalFRFrazier Life SciencesLOLongitude CapitalMEMESA VERDE VENTURE PARTNERSNONovartis Venture Fund

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

BiotechEvanston, US

Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)

Co-investorsCOCota CapitalLALatterell Venture PartnersSOSofinnova VenturesADAdams Street Partners

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDMDavid M. Tanen(Director, Promoter)HKHelen Kim(Director)

Co-investorsJEJeito CapitalVIVida VenturesTPTPG

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.

BiotechHealthtechWilmington, CN

Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)H(Hong (Kelsey) Chen(Chief Financial Officer)

BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)

Co-investorsHBHBM Healthcare InvestmentsHBHBM PartnersLALAVLILilly Asia VenturesRARA CapitalSASamsara BioCapital+3 more

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDGDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBABain Capital Life SciencesFOForesite CapitalSOSofinnova VenturesTHThe Column GroupWEWellington ManagementTHThird Rock Ventures

Omniox is an IND-stage biotherapeutics company developing its H-NOX platform into OMX oxygen delivery biologics that carry oxygen to hypoxic tissues where low oxygen levels drive disease.

BiotechMedical DevicesSan Francisco, US

JWJonathan Winger(Executive Officer, Director)inStephen Cary(Executive Officer, Director)

BoardJeffrey S. Samberg(Director)LMLaurence Marton(Director)Mitchell Mutz(Director)John Wesley(Director)

Co-investorsWAWavemaker Three-Sixty Health

Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.

AI & Machine LearningBiotechDeep TechUnited States, US

Co-investorsARARCH Venture PartnersCLClavystBioLELeaps by Bayer

BiotechMenlo Park, US

Ervin Epstein(Executive Officer, Director)inJean Tang(Director)Mark de Souza(Executive Officer)

BoardKatrin Andreasson(Director)

Co-investorsAIAisling Capital

RubiusTX provides independent reviews and research on Australian online casinos, focusing on licensing, player protections, payouts, and responsible gambling standards.

ConsumerGaming

BiotechMedical Devices

Co-investorsARARCH Venture Partners

BiotechDigital HealthMedical DevicesSeattle, US

PAPeter A. Thompson(Executive Officer, Director)in

Co-investorsPOPontifax Venture CapitalRARA CapitalUSUS Venture PartnersALAlexandriaNENextech InvestOROrbiMed

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.

AI & Machine LearningBiotechMedical DevicesWatertown, US

TATimothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)MSMarc Schwabish(Executive Officer)inPMPeter McNamara(Executive Officer)in

Co-investorsVIVida VenturesALAlly Bridge GroupCLClarus VenturesPOPolaris PartnersSOSoleus Capital

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in

BoardMichael Goller(Director)RHReid Huber(Director)inPTPeter Thompson(Director)in

Co-investorsOROrbiMedRARA CapitalNONovo HoldingsOSOsage University PartnersTHThird Rock Ventures

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

NENathaniel E. David(Executive Officer, Director)inDMDan Marquess(Executive Officer)inKLKeith Leonard(Executive Officer, Director)inTTTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsAGage1ALAlumni VenturesARARCH Venture PartnersCYCycad Group LLCKHKhosla VenturesVEVenrock+6 more